文献速递胃肠动力与功能性疾病消化道肿瘤与早癌

肠易激综合征与长期癌症风险:英国生物银行50万成人前瞻性队列研究

Irritable Bowel Syndrome and Long-Term Risk of Cancer: A Prospective Cohort Study Among 0.5 Million Adults in UK Biobank.
PubMed 文献 · Am J Gastroenterol · 2022-02-03

基于英国生物银行449,595名基线无炎症性肠病、乳糜泻及任何癌症的成人,其中22,338例(5.0%)诊断为肠易激综合征(IBS),中位随访12.2年。IBS组总体癌症风险未显著升高(校正HR 0.97,95%CI 0.93-1.00,P=0.062),癌症特异性死亡风险降低(HR 0.83,95%CI 0.76-0.91,P<0.001),消化系统癌症风险降低(HR 0.79,95%CI 0.71-0.89),结肠癌(HR 0.75,95%CI 0.62-0.90)和直肠癌(HR 0.68,95%CI 0.49-0.93)风险亦降低。

要点

  • IBS患者总体癌症风险未显著升高(校正HR 0.97,95%CI 0.93-1.00,P=0.062)。
  • IBS患者癌症特异性死亡风险降低(HR 0.83,95%CI 0.76-0.91,P<0.001)。
  • IBS患者消化系统癌症风险降低(HR 0.79,95%CI 0.71-0.89),结肠癌(HR 0.75)和直肠癌(HR 0.68)风险亦降低。

核心结论

  • 与一般人群相比,IBS不增加总体癌症风险。
  • IBS与结直肠癌发病风险及癌症特异性死亡风险降低相关。

研究设计与样本

  • 前瞻性队列研究,纳入英国生物银行基线无炎症性肠病、乳糜泻及任何癌症的参与者449,595名,其中IBS患者22,338例(5.0%)为暴露组,非IBS患者为参照组。
  • 采用Cox比例风险模型分析 incident 恶性肿瘤及相关死亡风险。

主要发现

  • 中位随访12.2年,IBS组发生癌症2,937例(11.47/1000人年),参照组60,556例(12.51/1000人年)。
  • IBS组癌症特异性死亡512例,非IBS组12,282例。
  • 校正后总体癌症HR为0.97(95%CI 0.93-1.00,P=0.062),癌症特异性死亡HR为0.83(95%CI 0.76-0.91,P<0.001)。
  • 消化系统癌症HR为0.79(95%CI 0.71-0.89),结肠癌HR为0.75(95%CI 0.62-0.90),直肠癌HR为0.68(95%CI 0.49-0.93)。
  • 按年龄和性别进行的亚组分析及敏感性分析结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To investigate the prospective association of irritable bowel syndrome (IBS) with long-term risk of overall, site-specific cancer and cancer-specific mortality in general population. METHODS: Participants free of inflammatory bowel disease, celiac disease, and any cancer at baseline from the UK Biobank were included, with patients with IBS as the exposure group and non-IBS patients as the reference group. The primary outcome was the incidence of overall cancer and cancer-specific mortality. Secondary outcomes included site-specific cancers and types of digestive cancers. The Cox proportional hazard model was used to investigate the associated risk of incident malignancies and related mortality. RESULTS: Among 449,595 participants, 22,338 (5.0%) were diagnosed with IBS. During a median of 12.2-year follow-up, 2,937 cases of incident cancer were identified in patients with IBS (11.47 per 1,000 person-years), compared with 60,556 cases in reference individuals (12.51 per 1,000 person-years). Of these cases, 512 and 12,282 cancer-specific deaths occurred in IBS and non-IBS groups. Compared with non-IBS, the adjusted hazard ratio for overall cancer and cancer-specific mortality was 0.97 (95% confidence interval: 0.93-1.00, P = 0.062) and 0.83 (0.76-0.91, P < 0.001) among patients with IBS. Specifically, decreased risk of digestive (0.79 [0.71-0.89]), particularly colon (0.75 [0.62-0.90]) and rectal (0.68 [0.49-0.93]), cancers was observed in patients with IBS. Further sensitivity analysis and subgroup analysis by age and sex indicated similar results. DISCUSSION: Compared with the general population, IBS does not increase the overall risk of cancer. Conversely, IBS is associated with lower risk of incident colorectal cancer and cancer-specific mortality.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wu S, Yuan C, Liu S, et al. Irritable Bowel Syndrome and Long-Term Risk of Cancer: A Prospective Cohort Study Among 0.5 Million Adults in UK Biobank. Am J Gastroenterol. 2022. PMID: 35130187. doi:10.14309/ajg.0000000000001674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。